GlobeNewswire by notified

PRESS RELEASE: NACON: WARHAMMER 40,000: INQUISITOR - MARTYR RELEASES ENHANCED VERSION FOR PLAYSTATION®5 AND XBOX SERIES S|X

Share

WARHAMMER 40,000: INQUISITOR - MARTYR RELEASES ENHANCED VERSION FOR PLAYSTATION®5 AND XBOX SERIES S|X

Lesquin, June 1st -- NACON and NeocoreGames announced today that Warhammer 40,000: Inquisitor - Martyr is coming to PlayStation®5 and Xbox Series S|X consoles later this year, including all 25 DLCs and extensions already released, alongside with enhanced new gen features.

These new and enhanced features include the following: 

  • Native 4k support
  • Higher resolution textures
  • Improved physics, including destructible environment
  • Cross-gen multiplayer modes
  • Fully utilizing DualSense controller on PlayStation 5

The new playable class DLC, announced back in 2021, is also coming to PlayStation 5 and Xbox Series S|X consoles at a later date. The new Sororitas class - an Inquisitor with an Adepta Sororitas background - will bring new class mechanics and item types to Warhammer 40,000: Inquisitor - Martyr as well.

Warhammer 40,000: Inquisitor - Martyr is a grim action-RPG, currently available on PC, PlayStation®4 and XboxOne, featuring multiple classes of the Inquisition who carry out the Emperor's will.

Watch the new gen console announcement trailer below
https://www.youtube.com/watch?v=laj3GnbEEA4

If you'd like to know more about Warhammer 40,000: Inquisitor - Martyr, or its stand-alone expansion Warhammer 40,000: Inquisitor - Martyr, check out one of our recent (or upcoming) Twitch streams, our updated Roadmap, or visit our Media Site. If you have any questions or would like to request a review code, feel free to contact us!

Name: Warhammer 40,000: Inquisitor - Martyr
Genre: Action-RPG
Developer: NeocoreGames
Publisher: NeocoreGames (PC), NACON (Xbox One, Xbox Series S|X, PS4, PS5)
Platforms: PC, Xbox One, Xbox Series S|X, PS4, PS5

Press contacts

Gergely Vas
PR Manager, NeocoreGames

gergely.vas@neocoregames.com

Patrik Csörnyei
PR Manager, NeocoreGames

patrik.csornyei@neocoregames.com

Lou Fortin
PR Manager, Nacon

lfortin@nacon.fr



ABOUT NEOCORE GAMES

NeocoreGames is an independent video game development company founded in 2005 with its headquarters located in Budapest, Hungary. Best known for The Incredible Adventures of Van Helsing series and Deathtrap and currently working on King Arthur: Knight's Tale, Warhammer 40,000: Inquisitor - Martyr and Warhammer 40,000: Inquisitor - Prophecy. NeocoreGames also developed Crusaders: Thy Kingdom Come, The Kings’ Crusade and the King Arthur: The Role-playing Wargame series.

ABOUT GAMES WORKSHOP

Games Workshop Group PLC (LSE:GAW.L), based in Nottingham, UK, produces the best fantasy miniatures in the world. Games Workshop designs, manufactures, retails, and distributes its range of Warhammer®: Age of Sigmar® and Warhammer® 40,000® games, miniature, novels and model kits through more than 523 of its own stores (branded Games Workshop® or Warhammer®), the www.games-workshop.com web store and independent retail channels in more than 50 countries worldwide. More information about Games Workshop and its other, related, brands and product ranges (including our publishing division ‘Black Library’ and our special resin miniatures studio ‘Forge World’) can be found at www.games-workshop.com.

ABOUT NACON

NACON is a company of the BIGBEN Group founded in 2019 to optimize its know-how through strong synergies in the video game market. By bringing together its 16 development studios, the publishing of AA video games, the design and distribution of premium gaming devices, NACON focuses 30 years of expertise at the service of players. https://www.nacongaming.com/

Warhammer 40,000: Inquisitor - Martyr © Copyright Games Workshop Limited 2022. Inquisitor - Martyr, the Inquisitor - Martyr logo, GW, Games Workshop, Space Marine, 40K, Warhammer, Warhammer 40,000, 40,000, the ‘Aquila’ Double-headed Eagle logo, and all associated logos, illustrations, images, names, creatures, races, vehicles, locations, weapons, characters, and the distinctive likeness thereof, are either ® or TM, and/or © Games Workshop Limited, variably registered around the world, and used under licence. All rights reserved to their respective owners.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Report – ERYTECH’s Combined Shareholders’ Meeting On June 24, 202224.6.2022 22:05:00 CEST | Press release

REPORT –ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022 Cambridge, MA (U.S.) and Lyon (France), June24, 2022 – ERYTECH Pharma (Nasdaq& Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announcedthat its Annual General Meeting was held on Friday, June 24, 2022. At the meeting, all resolutions for which the Board of Directors recommended a vote in favor were adopted, including: Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2021;Allocation of the financial year's results;Approval of the statutory auditors’ special report on regulated agreements and commitments with related parties;Approval of the elements of total compensation and benefits paid or allocated for the year ended December 31, 2021, to Gil BEYEN, Chief Executive Officer and Jean-Paul KRESS, Chairman of the Board;Approval of the compens

Cleantech Building Materials: Results of Annual General Meeting24.6.2022 14:54:27 CEST | Press release

24 June 2022 CLEANTECH BUILDING MATERIALS PLC, NASDAQ FIRST NORTH GROWTH MARKET, COPENHAGEN TICKER: CBM ISIN: GBOOBD1LVD21 CLEANTECH BUILDING MATERIALS PLC Results of Annual General Meeting The Annual General Meeting (“AGM”) of Cleantech Building Materials plc (“CBM” or the “Company”) was held in London earlier today, 24 June 2022. Details of the resolutions to be considered at the AGM were published in the Notice of AGM which was posted to Shareholders on 1 June 2022 and is available on the Company’s website: www.cbm-plc.com. All resolutions as set out in the Notice of AGM were duly passed without discussion. In particular, the following resolutions were passed at the AGM. The AGM resolved to authorise the directors of the Company to allot shares and grant rights to subscribe for, or convert any security, into shares. The directors of the Company sought authority for the purposes of section 551 of the Companies Act to exercise all the powers of the Company to allot shares and grant ri

Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia24.6.2022 13:13:19 CEST | Press release

With unique STAMP mechanism of action, Scemblix could provide a new option for patients in Europe with chronic myeloid leukemia (CML) who have suffered intolerance or inadequate response with at least two prior tyrosine kinase inhibitor treatments1 Positive opinion based on data from pivotal Phase III ASCEMBL trial, showing a near doubling in major molecular response rate for patients treated with Scemblix® (asciminib) vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) and more than three times lower discontinuation rate due to adverse reactions (5.8% vs 21.1%) at 24 weeks1 CHMP recommendation comes after the approval of Scemblix by the US FDA and other countries’ regulatory authorities, potentially broadening access for more patients to Novartis transformative therapies in CML Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing au

Clariant’s shareholders approve all agenda items24.6.2022 11:30:00 CEST | Press release

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Integrated Report and Group Consolidated Financial Statements for fiscal year 2021 approvedGünter von Au reelected as Chairman of the Board of DirectorsThree new candidates join the Board of Directors: Ahmed Mohamed Alumar, Roberto César Gualdoni, Naveena ShastriConfirmed distribution of CHF 0.40 per shareKPMG confirmed as statutory auditor from 2022 MUTTENZ, JUNE 24, 2022 Clariant, a focused, sustainable, and innovative specialty chemical company, today held its 27th Annual General Meeting (AGM) where the shareholders approved all agenda items and resolutions as proposed by the Board of Directors. The AGM was held virtually, where shareholders were able to exercise their rights exclusively via the independent proxy. Overall, 698'945'298 shares or around 70.19 % of the share capital of Clariant were represented. Günter von Au was reelected as Chairman of the Board of Directors. Additionally, three new members were voted to join by a large majo

Cool Company Ltd. – Mandatory Notification Of Trade24.6.2022 11:01:19 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 23 June 2022 acquired 7,865 shares in the Company at a price of NOK 90.274882 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,591,218 shares in the Company, equivalent to 38.97% of the Company’s shares. Please see the attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Primary insider notification form